September 2021

Table of Contents and Whole Issue PDF

Two prespecified literature searches were conducted via Ovid utilizing the following databases: MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews (CDSR). We selected studies reporting amputation-free survival (AFS) in patients with non-revascularizable Rutherford category 5/6 CLI at a minimum follow-up of 6 months.

An editorial commentary on Ghare et al's "Outcomes among patients with chronic critical limb ischemia with no revascularization option: systematic review and meta-analysis."

Despite medical advancements, PAD and CLI continue to increase globally. Treatment for PAD/CLI varies widely and patients with CTOs may be more challenging to treat, requiring specialized crossing techniques and modalities. The objective of this study was to determine the relationship between patients diagnosed with PAD/CLI, with CTOs, and subsequent long-term outcomes. 

Editorial commentary on Mustapha et al's "Chronic total occlusions: association between characteristics and long-term outcomes in critical limb ischemia."

This randomized, controlled trial was designed to compare the rate of postangiographic contrast-induced nephropathy between the intra-arterial injections of carbon dioxide and the iodinated contrast agent.

Amputation as the initial treatment of choice remains prevalent despite advances in revascularization techniques and medical therapy. We evaluated the 7-year mortality of patients undergoing major and minor lower-extremity amputations and determined the impact of risk factors on long-term mortality.

We review here the mechanism of action of OA, supporting clinical study evidence, and corresponding economic analyses.